Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen

Journal of Immunology

Volumn 179, Issue 5, 2007, Pages 2815-2823

  Tang, Yong ^a   Lou, Jianlong ^b   Alpaugh, R Katherine ^a   Robinson, Matthew K ^a   Marks, James D ^b   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; PROTEIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; FC RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; NEOPLASM; PHYSIOLOGY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, IGG;

EID: 38449107221     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.5.2815     Document Type: Article

References (53)

1. Miller, R. A., D. G. Maloney, R. Warnke, and R. Levy. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306: 517-522.
2. McLaughlin, P., A. J. Grillo-Lopez, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
3. Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792.
4. Coiffier, B. 2002. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin. Oncol. 29: 18-22.
5. Egen, J. G., M. S. Kuhns, and J. P. Allison. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3: 611-618.
6. Lundin, J., E. Kimby, M. Bjorkholm, P. A. Broliden, F. Celsing, V. Hjalmar, L. Mollgard, P. Rebello, G. Hale, H. Waldmann, et al. 2002. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (BCLL). Blood 100: 768-773.
7. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
8. Foon, K. A., X. D. Yang, L. M. Weiner, A. S. Belldegrun, R. A. Figlin, J. Crawford, E. K. Rowinsky, J. P. Dutcher, N. J. Vogelzang, J. Gollub, et al. 2004. Preclinical and clinical evaluations of ABX-EGF, a fully human antiepidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58: 984-990.
9. Hurwitz, H., L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350: 2335-2342.
10. Cunningham, D., Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351: 337-345.
11. Romond, E. H., E. A. Perez, J. Bryant, V. J. Suman, C. E. Geyer, Jr., N. E. Davidson, E. Tan-Chiu, S. Martino, S. Paik, P. A. Kaufman, et al. 2005. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353: 1673-1684.
12. Trcka, J., Y. Moroi, R. A. Clynes, S. M. Goldberg, A. Bergtold, M. A. Perales, M. Ma, C. R. Ferrone, M. C. Carroll, J. V. Ravetch, and A. N. Houghton. 2002. Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. Immunity 16: 861-868.
13. Ferrara, N., K. J. Hillan, and W. Novotny. 2005. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun. 333: 328-335.
14. Baselga, J. 2001. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer 37(Suppl 4): S16-S22.
15. Tyagi, P. 2005. Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer. Clin. Colorectal Cancer 5: 21-23.
16. Steplewski, Z., M. D. Lubeck, and H. Koprowski. 1983. Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science 221: 865-867.
17. Adams, G. P., and L. M. Weiner. 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23: 1147-1157.
18. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 99: 754-758.
19. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
20. Heijnen, I. A., and J. G. van de Winkel. 1997. Human IgG Fc receptors. Int. Rev. Immunol. 16: 29-55.
21. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446.
22. Sulica, A., P. Morel, D. Metes, and R. B. Herberman. 2001. Ig-binding receptors on human NK cells as effector and regulatory surface molecules. Int. Rev. Immunol. 20: 371-414.
23. Hernandez-Ilizaliturri, F. J., V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman. 2003. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin. Cancer Res. 9(16 Pt. 1): 5866-5873.
24. Masztalerz, A., N. Van Rooijen, W. Den Otter, and L. A. Everse. 2003. Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol. Immunother. 52: 235-242.
25. Kataoka, S., Y. Konishi, Y. Nishio, K. Fujikawa-Adachi, and A. Tominaga. 2004. Antitumor activity of eosinophils activated by IL-5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol. 23: 549-560.
26. Keilholz, U., J. Weber, J. H. Finke, D. I. Gabrilovich, W. M. Kast, M. L. Disis, J. M. Kirkwood, C. Scheibenbogen, J. Schlom, V. C. Maino, et al. 2002. Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J. Immunother. 25: 97-138.
27. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J. Biol. Chem. 276: 6591-6604.
28. Umana, P., J. Jean-Mairet, R. Moudry, H. Amstutz, and J. E. Bailey. 1999. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 17: 176-180.
29. Velders, M. P., C. M. van Rhijn, E. Oskam, G. J. Fleuren, S. O. Warnaar, and S. V. Litvinov. 1998. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br. J. Cancer 78: 478-483.
30. Schier, R., J. D. Marks, E. J. Wolf, G. Apell, C. Wong, J. E. McCartney, M. A. Bookman, J. S. Huston, L. L. Houston, L. M. Weiner, et al. 1995. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology 1: 73-81.
31. Schier, R., J. Bye, G. Apell, A. McCall, G. P. Adams, M. Malmqvist, L. M. Weiner, and J. D. Marks. 1996. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. 255: 28-43.
32. Schier, R., A. McCall, G. P. Adams, K. W. Marshall, H. Merritt, M. Yim, R. S. Crawford, L. M. Weiner, C. Marks, and J. D. Marks. 1996. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263: 551-567.
33. Adams, G. P., R. Schier, A. M. McCall, H. H. Simmons, E. M. Horak, R. K. Alpaugh, J. D. Marks, and L. M. Weiner. 2001. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61: 4750-4755.
34. McCall, A. M., G. P. Adams, A. R. Amoroso, U. B. Nielsen, L. Zhang, E. Horak, H. Simmons, R. Schier, J. D. Marks, and L. M. Weiner. 1999. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol. Immunol. 36: 433-445.
35. McCall, A. M., L. Shahied, A. R. Amoroso, E. M. Horak, H. H. Simmons, U. Nielson, G. P. Adams, R. Schier, J. D. Marks, and L. M. Weiner. 2001. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J. Immunol. 166: 6112-6117.
36. Shahied, L. S., Y. Tang, R. K. Alpaugh, R. Somer, D. Greenspon, and L. M. Weiner. 2004. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279: 53907-53914.
37. Frankel, A. E., D. B. Ring, F. Tringale, and S. T. Hsieh-Ma. 1985. Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biol. Response Mod. 4: 273-286.
38. Van Antwerp, J. J., and K. D. Wittrup. 2000. Fine affinity discrimination by yeast surface display and flow cytometry. Biotechnol. Prog. 16: 31-37.
39. Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99: 11346-11350.
40. Davies, J., and M. Reff. 2001. Chromosome localization and gene-copy-number quantification of three random integrations in Chinese-hamster ovary cells and their amplified cell lines using fluorescence in situ hybridization. Biotechnol. Appl. Biochem. 33: 99-105.
41. Nimmerjahn, F., and J. V. Ravetch. 2006. Fcγ receptors: old friends and new family members. Immunity 24: 19-28.
42. Iannello, A., and A. Ahmad. 2005. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 24: 487-499.
43. Ghetie, M. A., E. M. Podar, A. Ilgen, B. E. Gordon, J. W. Uhr, and E. S. Vitetta. 1997. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA 94: 7509-7514.
44. Mimura, K., K. Kono, M. Hanawa, M. Kanzaki, A. Nakao, A. Ooi, and H. Fujii. 2005. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin. Cancer Res. 11: 4898-4904.
45. Kawaguchi, Y., K. Kono, K. Mimura, H. Sugai, H. Akaike, and H. Fujii. 2006. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int. J. Cancer 120: 781-787.
46. Lazar, G. A., W. Dang, S. Karki, O. Vafa, J. S. Peng, L. Hyun, C. Chan, H. S. Chung, A. Eivazi, S. C. Yoder, et al. 2006. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. USA 103: 4005-4010.
47. Presta, L. G. 2002. Engineering antibodies for therapy. Curr. Pharm. Biotechnol. 3: 237-256.
48. Schuster, M., P. Umana, C. Ferrara, P. Brunker, C. Gerdes, G. Waxenecker, S. Wiederkum, C. Schwager, H. Loibner, G. Himmler, and G. C. Mudde. 2005. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 65: 7934-7941.
49. Weng, W.-K., J. Stavenhagen, S. Koenig, and R. Levy. 2005. Rituximab variants with re-engineered Fc with higher affinity to activating FcγR eliminate the functional difference between FcγR genotypes. ASH Annual Meeting Abstracts 106: 347.
50. Satoh, M., S. Iida, and K. Shitara. 2006. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. 6: 1161-1173.
51. Scallon, B. J., S. H. Tam, S. G. McCarthy, A. N. Cai, and T. S. Raju. 2007. Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality. Mol. Immunol. 44: 1524-1534.
52. Wiley, H. S. 2003. Trafficking of the ErbB receptors and its influence on signaling. Exp. Cell Res. 284: 78-88.
53. Friedman, L. M., A. Rinon, B. Schechter, L. Lyass, S. Lavi, S. S. Bacus, M. Sela, and Y. Yarden. 2005. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 102: 1915-1920.